Prostate-specific Antigen (PSA)

CPT: 84153
Print Share

Synonyms

  • PSA, Serum

Special Instructions

Values obtained with different assays should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy. This procedure does not provide serial monitoring; it is intended for one-time use only. If serial monitoring is required, please use the serial monitoring number 480145 to order.

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.


Expected Turnaround Time

Within 1 day



Related Documents


Specimen Requirements


Specimen

Serum


Volume

0.8 mL


Minimum Volume

0.3 mL (Note: This volume does not allow for repeat testing.)


Container

Red-top tube or gel-barrier tube


Collection

If a red-top tube is used, transfer separated serum to a plastic transport tube.


Storage Instructions

Maintain specimen at room temperature.


Stability Requirements

Temperature

Period

Room temperature

7 days

Refrigerated

7 days

Frozen

14 days

Freeze/thaw cycles

Stable x3


Causes for Rejection

Plasma or whole blood specimen; hemolysis


Test Details


Use

Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells lining the prostatic ducts and acini. Normally, it is secreted into the prostatic ducts and is present only in prostate tissue, prostatic fluid, and seminal plasma. PSA is produced by normal, hyperplastic, and cancerous prostatic tissue. PSA is used as a tumor marker for the early detection of prostate cancer and in other areas of prostate disease management.1 The Prostate-Specific Antigen Best Practice Statement: 2009 Update published by the American Urologic Association1 describes the use of PSA testing for:

• The evaluation of men at risk for prostate cancer

• Assistance in pretreatment staging

• Risk assessment posttreatment monitoring

• Use as a guide in management of men who recur after primary or secondary therapy


Limitations

The measured PSA value of a patient's sample can vary depending on the testing procedure used.2 PSA values determined on patient's samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations.2 Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.1 The PSA value should be used in conjunction with information from clinical evaluation and other diagnostic procedures.1

PSA levels can be elevated in patients with prostatitis.1 Treatment with antibiotics will decrease PSA by approximately 30% in men whose PSA elevation is due to prostatitis alone.1 PSA can also be increased in men with benign prostatic hyperplasia (BPH).1 PSA can be increased due to urethral or prostatic trauma.1 Prostate biopsy can cause substantial elevation of PSA levels.1 Cystoscopy may increase PSA levels immediately after testing.1 Ejaculation and DRE have been reported to increase PSA levels but studies have shown the effects to be variable or insignificant.1 PSA testing can be performed with reasonable accuracy after rectal examination.1

Surgical castration or medical castration (with LHRH-agonist or antiandrogen therapy) can lower PSA levels dramatically.1 Finasteride and dutasteride (5-α reductase inhibitors) can lower PSA levels by approximately 50% regardless of the dose.1 Prostatic intraepithelial neoplasia (PIN) does not increase PSA levels.1


Methodology

Electrochemiluminescence immunoassay (ECLIA)


Reference Interval

Male: 0−4.0 ng/mL (Note: This interval is not intended to be used as a reference for posttreatment follow-up and monitoring of patients.)

According to the American Urological Association, serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value ≥0.2 ng/mL followed by a subsequent confirmatory PSA value ≥0.2 ng/mL.


Footnotes

1. Prostate-Specific Antigen Best Practice Statement: 2009 Update, American Urologic Association. Available at: http://www.auanet.org/content/guideline-and-quality-care/clinical-guidelines/main-reports/psa09.pdf. Accessed March 3, 2011. 2467013
2. Total PSA on Elecsys 1010/2010 and Modular Analytics E170 [package insert]. 2007-08, V 4. Indianapolis, Ind: Roche Diagnostics;2007. 1707989

References

Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200. 20141676

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
010322 Prostate-Specific Ag, Serum 2857-1 010334 Prostate Specific Ag, Serum ng/mL 2857-1

For Providers

Please login to order a test.

 

© 2019  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf